247 related articles for article (PubMed ID: 29769258)
41. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
42. Deciphering targeting rules of splicing modulator compounds: case of TG003.
Sakuma M; Iida K; Hagiwara M
BMC Mol Biol; 2015 Sep; 16():16. PubMed ID: 26400733
[TBL] [Abstract][Full Text] [Related]
43. Two nucleus-localized CDK-like kinases with crucial roles for malaria parasite erythrocytic replication are involved in phosphorylation of splicing factor.
Agarwal S; Kern S; Halbert J; Przyborski JM; Baumeister S; Dandekar T; Doerig C; Pradel G
J Cell Biochem; 2011 May; 112(5):1295-310. PubMed ID: 21312235
[TBL] [Abstract][Full Text] [Related]
44. Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.
Nonomiya Y; Noguchi K; Tanaka N; Kasagaki T; Katayama K; Sugimoto Y
Cancer Sci; 2016 Dec; 107(12):1877-1887. PubMed ID: 27699933
[TBL] [Abstract][Full Text] [Related]
45. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Taira N; Mimoto R; Kurata M; Yamaguchi T; Kitagawa M; Miki Y; Yoshida K
J Clin Invest; 2012 Mar; 122(3):859-72. PubMed ID: 22307329
[TBL] [Abstract][Full Text] [Related]
46. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway.
Weg-Remers S; Ponta H; Herrlich P; König H
EMBO J; 2001 Aug; 20(15):4194-203. PubMed ID: 11483522
[TBL] [Abstract][Full Text] [Related]
47. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
48. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.
Sheng X; Nenseth HZ; Qu S; Kuzu OF; Frahnow T; Simon L; Greene S; Zeng Q; Fazli L; Rennie PS; Mills IG; Danielsen H; Theis F; Patterson JB; Jin Y; Saatcioglu F
Nat Commun; 2019 Jan; 10(1):323. PubMed ID: 30679434
[TBL] [Abstract][Full Text] [Related]
49. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
50. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
[TBL] [Abstract][Full Text] [Related]
51. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
Prak K; Kriston-Vizi J; Chan AW; Luft C; Costa JR; Pengo N; Ketteler R
Biochemistry; 2016 Jan; 55(3):608-17. PubMed ID: 26701387
[TBL] [Abstract][Full Text] [Related]
52. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
53. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.
Walter A; Chaikuad A; Loaëc N; Preu L; Knapp S; Meijer L; Kunick C; Koch O
Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000414
[TBL] [Abstract][Full Text] [Related]
54. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
[TBL] [Abstract][Full Text] [Related]
55. Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation.
Nam SY; Seo HH; Park HS; An S; Kim JY; Yang KH; Kim CS; Jeong M; Jin YW
J Biol Chem; 2010 Oct; 285(41):31157-63. PubMed ID: 20682768
[TBL] [Abstract][Full Text] [Related]
56. Exploring the roles of the Cdc2-like kinases in cancers.
Blackie AC; Foley DJ
Bioorg Med Chem; 2022 Sep; 70():116914. PubMed ID: 35872347
[TBL] [Abstract][Full Text] [Related]
57. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
58. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
Aubol BE; Keshwani MM; Fattet L; Adams JA
Biochem J; 2018 Feb; 475(3):677-690. PubMed ID: 29335301
[TBL] [Abstract][Full Text] [Related]
59. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells.
Domínguez-Cáceres MA; García-Martínez JM; Calcabrini A; González L; Porque PG; León J; Martín-Pérez J
Oncogene; 2004 Sep; 23(44):7378-90. PubMed ID: 15286700
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of N,N'-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases.
Coulibaly WK; Paquin L; Bénie A; Bekro YA; Durieu E; Meijer L; Bazureau JP
Eur J Med Chem; 2012 Dec; 58():581-90. PubMed ID: 23174317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
